VHAQ vs. MNOV, MURA, DERM, CARM, LTRN, ASMB, LABP, SCYX, KRON, and EQ
Should you be buying Viveon Health Acquisition stock or one of its competitors? The main competitors of Viveon Health Acquisition include MediciNova (MNOV), Mural Oncology (MURA), Journey Medical (DERM), Carisma Therapeutics (CARM), Lantern Pharma (LTRN), Assembly Biosciences (ASMB), Landos Biopharma (LABP), SCYNEXIS (SCYX), Kronos Bio (KRON), and Equillium (EQ). These companies are all part of the "pharmaceutical preparations" industry.
MediciNova (NASDAQ:MNOV) and Viveon Health Acquisition (NYSE:VHAQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.
MediciNova's return on equity of 0.00% beat Viveon Health Acquisition's return on equity.
In the previous week, MediciNova had 4 more articles in the media than Viveon Health Acquisition. MarketBeat recorded 4 mentions for MediciNova and 0 mentions for Viveon Health Acquisition. MediciNova's average media sentiment score of 0.00 beat Viveon Health Acquisition's score of -0.09 indicating that Viveon Health Acquisition is being referred to more favorably in the news media.
9.9% of MediciNova shares are held by institutional investors. Comparatively, 22.1% of Viveon Health Acquisition shares are held by institutional investors. 16.9% of MediciNova shares are held by company insiders. Comparatively, 75.3% of Viveon Health Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
MediciNova has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Viveon Health Acquisition has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500.
Viveon Health Acquisition has lower revenue, but higher earnings than MediciNova.
MediciNova received 209 more outperform votes than Viveon Health Acquisition when rated by MarketBeat users.
Summary
Viveon Health Acquisition beats MediciNova on 6 of the 10 factors compared between the two stocks.
Get Viveon Health Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for VHAQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VHAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viveon Health Acquisition Competitors List
Related Companies and Tools
